| Place of Origin: | China |
|---|---|
| Brand Name: | HNB |
| Certification: | ISO |
| Model Number: | Telmisartan |
| Minimum Order Quantity: | 1KG |
| Price: | Negotiable |
| Packaging Details: | Aluminum foil bag |
| Delivery Time: | Usually7-10days |
| Payment Terms: | L/C, D/A, D/P, T/T, , MoneyGram |
| Supply Ability: | 5000kg/Month |
| CAS: | 144701-48-4 | Mf: | C33H30N4O2 |
|---|---|---|---|
| MW: | 514.617 | Specification: | ≥98% |
| Einecs No.: | N/A | Appearance: | White Crystalline Powder |
CAS 144701-48-4 Circulatory system medication Anti hypertensive drug Telmisartan Powder
|
Product Name |
Telmisartan |
|
Function |
APIs |
|
Specification |
99%Tech |
|
Chemical Name |
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid |
|
CAS No. |
|
|
Empirical Formula |
C33H30N4O2 |
|
Toxicology |
There is no greater than or equal to 0 in this product. A 1% component has been identified by IARC as a probable or certain human carcinogen. |
|
Applications |
Telmisartan is an effective angiotensin II type 1 receptor antagonist with IC50 value of 9.2 nM. Telmisartan can inhibit the activity of angiotensin II type 1 receptor. |
|
Package |
1kg/bag,25kg/drum |
The Introductction of Telmisartan:
Telmisartan,chemically named 4 '-[4-methyl-6 -(1-methyl-1h-benzimidazol-2-yl) -2-propyl - 1h-benzimidazol-1-yl] biphenyl - 2-carboxylic acid, molecular formula is C33H30N4O2, white or white crystalline powder, odorless, tasteless. Soluble in trichloromethane, slightly soluble in dichloromethane or dimethylformamide, slightly soluble in methanol, very slightly soluble in ethanol, almost insoluble in water, soluble in 1mol/L sodium hydroxide solution, very slightly soluble in 0.1mol/L hydrochloric acid solution.
The Application & Function of Telmisartan:
Non-peptide angiotensin ⅱ receptor antagonists selectively and irreversibly block ATI receptors without affecting other receptor systems. For mild to moderate hypertension. Telmisartan, a novel antihypertensive drug, is a specific angiotensin ⅱ receptor antagonist (AT ⅰ type) and is used in the treatment of essential hypertension. The replacement angiotensin ⅱ receptor binds with high affinity to the AT ⅰ receptor subtype (known angiotensin ⅱ action site). Telmisartan has no site agonist effect on AT ⅰ receptor site, and selectively binds to AT ⅰ receptor for a long time. There is no affinity for other receptors, including AT2 and other LESS characteristic AT receptors. The function of these other receptors is unknown, as is the possible overstimulation effect of telmisartan on angiotensin II levels.
Application:
Telmisartan did not inhibit renin in human plasma or block ion channels. It did not inhibit angiotensin converting enzyme ⅱ, which could also degrade the adverse reactions caused by bradykinin enhancement. The elevated blood pressure induced by angiotensin ⅱ was almost completely inhibited by telmisartan 80mg in human. The inhibitory effect lasted 24 hours and could still be detected at 48 hours. The antihypertensive effect was gradually obvious within 3 hours after the first dose. Maximum hypotensive effects are achieved 4 weeks after the start of treatment and can be maintained over the long term. If treatment is abruptly interrupted, blood pressure gradually returns to pre-treatment levels after several days without rebound hypertension. In clinical trials that directly compared the two hypertension drugs, the incidence of dry cough was significantly lower in patients treated with angiotensin-converting enzyme inhibitors.
The COA of Telmisartan
